Raymond James Financial
CPRX

Raymond James Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Raymond James Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.6M Buy
889,940
+48,026
+6% +$1.14M 0.01% 1410
2025
Q4 		$19.6M Buy
841,914
+68,584
+9% +$1.53M 0.01% 1455
2025
Q3 		$15.2M Sell
773,330
-71,718
-8% -$1.47M ﹤0.01% 1607
2025
Q2 		$18.3M Buy
845,048
+404,525
+92% +$9.55M 0.01% 1438
2025
Q1 		$10.7M Buy
440,523
+110,543
+33% +$2.49M ﹤0.01% 1767
2024
Q4 		$6.89M Buy
+329,980
New +$7.09M ﹤0.01% 2108

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Raymond James Financial's CPRX Position: Q1 2026 in Review

Raymond James Financial increased its Catalyst Pharmaceutical (CPRX) stake by 5.7% in Q1 2026, buying an estimated $1.14M and bringing the position to 889,940 shares worth $21.6M. The position accounts for 0.01% of the portfolio, ranked #1410.

Raymond James Financial first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Raymond James Financial held 889,940 shares of Catalyst Pharmaceutical worth $21.6M as of Q1 2026.
  • Raymond James Financial bought 48,026 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.14M.
  • Catalyst Pharmaceutical made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1410 holding.
  • Raymond James Financial first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.